Octave Bioscience
octavebio.com
Actively hiring
Financial Services
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Octave Bioscience is advancing multiple sclerosis care through precision neurology. The Octave MSDA Test measures 18 blood biomarkers to inform MS care.
News
Octave Bioscience Names Jennifer Mellum Vice President of Marketing as Precision Neurology Platform Scales
Read more
Report
Octave Bioscience Accelerates Precision Neurology Momentum, Appoints Zachary Fernandes as VP of Business Development to Scale Strategic Partnerships
MENLO PARK, Calif., May 26, 2026--Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker-driven solutions for multiple sclerosis, Parkinson
Read more
Report
Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial
MENLO PARK, Calif., January 08, 2026--Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today announced the appoint
Read more
Report
Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial
Read more
Report
Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave Multiple Sclerosis Disease Activity (MSDA) Test Across the United States
Octave Bioscience, a commercial-stage precision care company pioneering a new standard for managing multiple sclerosis and other neurodegenerative diseases such as Parkinson' s disease, today announced a strategic collaboration with Quest Diagnostics, a l
Read more
Report
Octave Bioscience: $35 Million Raised For Advancing Precision Care For Neurological Diseases
Octave Bioscience, a company focused on precision medicine for neurodegenerative conditions, has announced the successful close of a $35.6 million Series C equity financing round. In addition to this funding, the company has secured a $15.5 million non-di
Read more
Report
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis
The multifaceted nature of multiple sclerosis requires quantitative biomarkers that can provide insights related to diverse physiological pathways. To this end, proteomic analysis of deeply-phenotyped serum samples, biological pathway modeling, and networ
Read more
Report
Octave Bioscience: Precision Care Company Extends $30 Million Series B Funding Round
Octave Bioscience - a leading precision care company focused on delivering a new standard of care for multiple sclerosis (MS) and other neurodegenerative diseases - recently announced the closing of a $30 million extension to its Series B funding round.
Read more
Report
Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases
--Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures, has invested in Octave Bioscience, the developer of a first-of-its-kind platform to accurately and objectively measure and help
Read more
Report